Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Quantitative bone scan imaging using BSI and BUV: an approach to evaluate ARONJ early.

Yamamoto Y, Mitsunaga S, Horikawa A, Hino A, Kurihara H.

Ann Nucl Med. 2019 Nov 8. doi: 10.1007/s12149-019-01417-x. [Epub ahead of print]

PMID:
31705367
2.

Germline mutations in cancer-predisposition genes in patients with biliary tract cancer.

Terashima T, Umemoto K, Takahashi H, Hosoi H, Takai E, Kondo S, Sakamoto Y, Mitsunaga S, Ohno I, Hashimoto Y, Sasaki M, Ikeda M, Shimada K, Kaneko S, Yachida S, Sugano K, Okusaka T, Morizane C.

Oncotarget. 2019 Oct 15;10(57):5949-5957. doi: 10.18632/oncotarget.27224. eCollection 2019 Oct 15.

3.

Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial.

Niikura N, Nakatukasa K, Amemiya T, Watanabe KI, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Shibuya Y, Hayashi N, Naito M, Kashiwabara K, Yamashita T, Umeda M, Mukai H, Ota Y.

Oncologist. 2019 Oct 8. pii: theoncologist.2019-0382. doi: 10.1634/theoncologist.2019-0382. [Epub ahead of print]

PMID:
31594912
4.

Impact of Proton Beam Irradiation of an Anatomic Subsegment of the Liver for Hepatocellular Carcinoma.

Hojo H, Raturi V, Nakamura N, Arahira S, Akita T, Mitsunaga S, Nakamura M, Motegi A, Kageyama SI, Zenda S, Okumura M, Ikeda M, Akimoto T.

Pract Radiat Oncol. 2019 Oct 1. pii: S1879-8500(19)30276-0. doi: 10.1016/j.prro.2019.09.012. [Epub ahead of print]

PMID:
31585204
5.

Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study.

Iizumi S, Kuchiba A, Okusaka T, Ikeda M, Sakamoto Y, Kondo S, Morizane C, Ueno H, Osame K, Mitsunaga S, Ohno I, Imaoka H, Hashimoto Y, Takahashi H, Sasaki M, Ohashi K.

Intern Med. 2019 Sep 1;58(17):2435-2441. doi: 10.2169/internalmedicine.2539-18. Epub 2019 Jun 7.

6.

A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol.

Miura S, Naito T, Mitsunaga S, Omae K, Mori K, Inano T, Yamaguchi T, Tatematsu N, Okayama T, Morikawa A, Mouri T, Tanaka H, Kimura M, Imai H, Mizukami T, Imoto A, Kondoh C, Shiotsu S, Okuyama H, Ueno M, Takahashi T, Tsuji T, Aragane H, Inui A, Higashiguchi T, Takayama K.

BMC Cancer. 2019 May 31;19(1):528. doi: 10.1186/s12885-019-5762-6.

7.

Generation of Human Primordial Germ Cell-like Cells at the Surface of Embryoid Bodies from Primed-pluripotency Induced Pluripotent Stem Cells.

Mitsunaga S, Shioda K, Isselbacher KJ, Hanna JH, Shioda T.

J Vis Exp. 2019 Jan 11;(143). doi: 10.3791/58297.

PMID:
30688291
8.

Endoscopic Ultrasound-Guided Gallbladder Drainage for Aberrant Right Posterior Duct Obstruction Developing after Placement of a Covered Self-Expandable Metallic Stent in a Patient with Distal Biliary Obstruction.

Suzuki Y, Hashimoto Y, Shibuki T, Kan M, Kimura G, Umemoto K, Watanabe K, Sasaki M, Takahashi H, Imaoka H, Ohno I, Mitsunaga S, Ikeda M.

Case Rep Gastroenterol. 2018 Nov 28;12(3):722-728. doi: 10.1159/000492215. eCollection 2018 Sep-Dec.

9.

Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non-small-cell lung cancer.

Naito T, Mitsunaga S, Miura S, Tatematsu N, Inano T, Mouri T, Tsuji T, Higashiguchi T, Inui A, Okayama T, Yamaguchi T, Morikawa A, Mori N, Takahashi T, Strasser F, Omae K, Mori K, Takayama K.

J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):73-83. doi: 10.1002/jcsm.12351. Epub 2018 Oct 18.

10.

Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy.

Suzuki Y, Kan M, Kimura G, Umemoto K, Watanabe K, Sasaki M, Takahashi H, Hashimoto Y, Imaoka H, Ohno I, Mitsunaga S, Ikeda M.

J Gastroenterol. 2019 Mar;54(3):281-290. doi: 10.1007/s00535-018-1518-3. Epub 2018 Oct 8.

11.

Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors.

Imaoka H, Sasaki M, Takahashi H, Hashimoto Y, Ohno I, Mitsunaga S, Watanabe K, Umemoto K, Kimura G, Suzuki Y, Kan M, Ikeda M.

Oncologist. 2019 Jan;24(1):47-53. doi: 10.1634/theoncologist.2017-0651. Epub 2018 Aug 2. Review.

PMID:
30072388
12.

Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.

Ikeda M, Ohno I, Ueno H, Mitsunaga S, Hashimoto Y, Okusaka T, Kondo S, Sasaki M, Sakamoto Y, Takahashi H, Hara R, Kobayashi S, Nakamura O, Morizane C.

Invest New Drugs. 2019 Feb;37(1):109-117. doi: 10.1007/s10637-018-0634-5. Epub 2018 Jul 11.

PMID:
29995287
13.

Evolutionarily diverse mechanisms of germline specification among mammals: what about us?

Mitsunaga S, Shioda T.

Stem Cell Investig. 2018 Apr 24;5:12. doi: 10.21037/sci.2018.04.03. eCollection 2018. No abstract available.

14.

Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer.

Miura T, Mitsunaga S, Ikeda M, Ohno I, Takahashi H, Suzuki H, Irisawa A, Kuwata T, Ochiai A.

Support Care Cancer. 2018 Nov;26(11):3811-3817. doi: 10.1007/s00520-018-4248-4. Epub 2018 May 18.

PMID:
29777378
15.

The prognostic impact of differentiation at the invasive front of biliary tract cancer.

Okubo S, Mitsunaga S, Kato Y, Kojima M, Sugimoto M, Gotohda N, Takahashi S, Hayashi R, Konishi M.

J Surg Oncol. 2018 May;117(6):1278-1287. doi: 10.1002/jso.24946. Epub 2018 Mar 24.

PMID:
29572828
16.

Neural Invasion Spreads Macrophage-Related Allodynia via Neural Root in Pancreatic Cancer.

Miura T, Mitsunaga S, Ikeda M, Ohno I, Takahashi H, Kuwata T, Ochiai A.

Anesth Analg. 2018 May;126(5):1729-1738. doi: 10.1213/ANE.0000000000002803.

PMID:
29570153
17.

EUS-guided n-butyl-2-cyanoacrylate injection therapy for ruptured isolated left gastric artery pseudoaneurysm.

Hashimoto Y, Ohno I, Takahashi H, Sasaki M, Imaoka H, Watanabe K, Umemoto K, Kimura G, Mitsunaga S, Ikeda M.

Endosc Ultrasound. 2019 Jan-Feb;8(1):58-59. doi: 10.4103/eus.eus_109_17. No abstract available.

18.

Prenatal Exposure to Bisphenol A Disrupts Naturally Occurring Bimodal DNA Methylation at Proximal Promoter of fggy, an Obesity-Relevant Gene Encoding a Carbohydrate Kinase, in Gonadal White Adipose Tissues of CD-1 Mice.

Taylor JA, Shioda K, Mitsunaga S, Yawata S, Angle BM, Nagel SC, Vom Saal FS, Shioda T.

Endocrinology. 2018 Feb 1;159(2):779-794. doi: 10.1210/en.2017-00711.

19.

Relevance of iPSC-derived human PGC-like cells at the surface of embryoid bodies to prechemotaxis migrating PGCs.

Mitsunaga S, Odajima J, Yawata S, Shioda K, Owa C, Isselbacher KJ, Hanna JH, Shioda T.

Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9913-E9922. doi: 10.1073/pnas.1707779114. Epub 2017 Oct 30.

20.

Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms.

Imaoka H, Sasaki M, Takahashi H, Hashimoto Y, Ohno I, Mitsunaga S, Watanabe K, Umemoto K, Kimura G, Suzuki Y, Ikeda M.

Endocr Relat Cancer. 2017 Sep;24(9):475-483. doi: 10.1530/ERC-17-0197. Epub 2017 Jul 6.

PMID:
28684542
21.

Predictive Significance of Tumor Depth and Budding for Late Lymph Node Metastases in Patients with Clinical N0 Early Oral Tongue Carcinoma.

Hori Y, Kubota A, Yokose T, Furukawa M, Matsushita T, Takita M, Mitsunaga S, Mizoguchi N, Nonaka T, Nakayama Y, Oridate N.

Head Neck Pathol. 2017 Dec;11(4):477-486. doi: 10.1007/s12105-017-0814-1. Epub 2017 Apr 3.

22.

A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma.

Ikeda M, Okusaka T, Sato Y, Furuse J, Mitsunaga S, Ueno H, Morizane C, Inaba Y, Kobayashi T, Arai Y.

Jpn J Clin Oncol. 2017 Jun 1;47(6):512-519. doi: 10.1093/jjco/hyx038.

PMID:
28334948
23.

Transarterial (Chemo)Embolization for Liver Metastases in Patients with Neuroendocrine Tumors.

Okuyama H, Ikeda M, Takahashi H, Ohno I, Hashimoto Y, Mitsunaga S, Sakamoto Y, Kondo S, Morizane C, Ueno H, Kobayashi T, Arai Y, Okusaka T.

Oncology. 2017;92(6):353-359. doi: 10.1159/000463388. Epub 2017 Mar 23.

PMID:
28329738
24.

Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine.

Ikeda M, Sato A, Mochizuki N, Toyosaki K, Miyoshi C, Fujioka R, Mitsunaga S, Ohno I, Hashimoto Y, Takahashi H, Hasegawa H, Nomura S, Takahashi R, Yomoda S, Tsuchihara K, Kishino S, Esumi H.

Cancer Sci. 2016 Dec;107(12):1818-1824. doi: 10.1111/cas.13086. Epub 2016 Dec 19.

25.

Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment.

Okusaka T, Otsuka T, Ueno H, Mitsunaga S, Sugimoto R, Muro K, Saito I, Tadayasu Y, Inoue K, Loembé AB, Ikeda M.

Cancer Sci. 2016 Dec;107(12):1791-1799. doi: 10.1111/cas.13077. Epub 2016 Dec 12.

26.

Erasure of DNA methylation, genomic imprints, and epimutations in a primordial germ-cell model derived from mouse pluripotent stem cells.

Miyoshi N, Stel JM, Shioda K, Qu N, Odajima J, Mitsunaga S, Zhang X, Nagano M, Hochedlinger K, Isselbacher KJ, Shioda T.

Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9545-50. doi: 10.1073/pnas.1610259113. Epub 2016 Aug 2. Erratum in: Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):E5697. Odahima, Junko [corrected to Odajima, Junko].

27.

Screening rate for hepatitis B virus infection in patients undergoing chemotherapy in Japan.

Ikeda M, Yamamoto H, Kaneko M, Oshima H, Takahashi H, Umemoto K, Watanabe K, Hashimoto Y, Ohno I, Mitsunaga S, Okusaka T.

Int J Clin Oncol. 2016 Dec;21(6):1162-1166. Epub 2016 Jun 3.

PMID:
27260010
28.

Correction of the HLA-DQB1*04:01:01 sequence at position 79 in exon 1.

Okudaira Y, Hosomichi K, Ozaki Y, Shiina T, Mitsunaga S.

HLA. 2016 Jan;87(1):57-8. doi: 10.1111/tan.12712. Epub 2015 Nov 18.

PMID:
26814416
29.

Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.

Shoji H, Morizane C, Sakamoto Y, Kondo S, Ueno H, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Ikeda M, Okusaka T.

Jpn J Clin Oncol. 2016 Feb;46(2):132-7. doi: 10.1093/jjco/hyv179. Epub 2015 Dec 18.

PMID:
26685318
30.

Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future.

Ikeda M, Mitsunaga S, Ohno I, Hashimoto Y, Takahashi H, Watanabe K, Umemoto K, Okusaka T.

Diseases. 2015 Dec 1;3(4):360-381. doi: 10.3390/diseases3040360. Review.

31.

C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer.

Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Takahashi H, Okuyama H, Ueno H, Morizane C, Kondo S, Sakamoto Y, Okusaka T, Ochiai A.

Pancreas. 2016 Jan;45(1):110-6. doi: 10.1097/MPA.0000000000000465.

PMID:
26566216
32.

Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.

Ikeda M, Okusaka T, Mitsunaga S, Ueno H, Tamai T, Suzuki T, Hayato S, Kadowaki T, Okita K, Kumada H.

Clin Cancer Res. 2016 Mar 15;22(6):1385-94. doi: 10.1158/1078-0432.CCR-15-1354. Epub 2015 Oct 23.

33.

Unique characteristics in Japanese dermatitis herpetiformis.

Ohata C, Ishii N, Niizeki H, Shimomura Y, Furumura M, Inoko H, Mitsunaga S, Saiki M, Shigeta M, Fujiwara S, Yamakawa K, Kobayashi S, Kamata M, Inaba M, Ito T, Uhara H, Watanabe R, Ohtoshi S, Ohashi T, Tanaka T, Suzuki M, Sitaru C, Kárpáti S, Zone JJ, Hashimoto T.

Br J Dermatol. 2016 Jan;174(1):180-3. doi: 10.1111/bjd.13965. Epub 2015 Nov 1. No abstract available.

PMID:
26119216
34.

Aggregation of rare/low-frequency variants of the mitochondria respiratory chain-related proteins in rheumatoid arthritis patients.

Mitsunaga S, Hosomichi K, Okudaira Y, Nakaoka H, Suzuki Y, Kuwana M, Sato S, Kaneko Y, Homma Y, Oka A, Shiina T, Inoko H, Inoue I.

J Hum Genet. 2015 Aug;60(8):449-54. doi: 10.1038/jhg.2015.50. Epub 2015 May 28.

PMID:
26016412
35.

Cytotoxic chemotherapy for pancreatic neuroendocrine tumors.

Okusaka T, Ueno H, Morizane C, Kondo S, Sakamoto Y, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Ikeda M.

J Hepatobiliary Pancreat Sci. 2015 Aug;22(8):628-33. doi: 10.1002/jhbp.257. Epub 2015 May 3. Review.

PMID:
25940377
36.

Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels.

Miura T, Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Takahashi H, Furuse J, Inagaki M, Higashi S, Kato H, Terao K, Ochiai A.

Pancreas. 2015 Jul;44(5):756-63. doi: 10.1097/MPA.0000000000000335.

PMID:
25931255
37.

Cost-efficient multiplex PCR for routine genotyping of up to nine classical HLA loci in a single analytical run of multiple samples by next generation sequencing.

Ozaki Y, Suzuki S, Kashiwase K, Shigenari A, Okudaira Y, Ito S, Masuya A, Azuma F, Yabe T, Morishima S, Mitsunaga S, Satake M, Ota M, Morishima Y, Kulski JK, Saito K, Inoko H, Shiina T.

BMC Genomics. 2015 Apr 18;16:318. doi: 10.1186/s12864-015-1514-4.

38.

[A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer].

Tanaka H, Mitsunaga S, Kobayashi M, Funazaki H, Katayama S, Kuwahara A, Okuyama H, Takahashi H, Ohno I, Shimizu S, Sakamoto Y, Kondo S, Morizane C, Ueno H, Okusaka T, Ochiai A, Ikeda M.

Gan To Kagaku Ryoho. 2015 Mar;42(3):313-7. Japanese.

PMID:
25812499
39.

Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma.

Ikeda M, Okuyama H, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Kondo S, Morizane C, Ueno H, Okusaka T.

J Hepatobiliary Pancreat Sci. 2015 Aug;22(8):623-7. doi: 10.1002/jhbp.228. Epub 2015 Mar 5. Review.

PMID:
25755102
40.

Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in patients with advanced pancreatic cancer: a retrospective study.

Shinohara A, Ikeda M, Okuyama H, Kobayashi M, Funazaki H, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Ichida Y, Takahashi K, Okusaka T, Saitoh S.

Am J Clin Dermatol. 2015 Jun;16(3):221-9. doi: 10.1007/s40257-015-0116-x.

PMID:
25687689
41.

Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma.

Okusaka T, Ueno H, Ikeda M, Mitsunaga S, Ozaka M, Ishii H, Yokosuka O, Ooka Y, Yoshimoto R, Yanagihara Y, Okita K.

Hepatol Res. 2015 Dec;45(13):1283-91. doi: 10.1111/hepr.12504. Epub 2015 Mar 24.

PMID:
25676869
42.

Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib.

Okuyama H, Ikeda M, Kuwahara A, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Senda S, Okusaka T.

Oncology. 2015;88(4):241-6. doi: 10.1159/000369351. Epub 2014 Dec 11.

PMID:
25503567
43.

Genome-wide linkage and exome analyses identify variants of HMCN1 for splenic epidermoid cyst.

Omer WH, Narita A, Hosomichi K, Mitsunaga S, Hayashi Y, Yamashita A, Krasniqi A, Iwasaki Y, Kimura M, Inoue I.

BMC Med Genet. 2014 Oct 23;15:115. doi: 10.1186/s12881-014-0115-4.

44.

Possible association between dysfunction of vitamin D binding protein (GC Globulin) and migraine attacks.

Nagata E, Fujii N, Hosomichi K, Mitsunaga S, Suzuki Y, Mashimo Y, Tsukamoto H, Satoh T, Osawa M, Inoue I, Hata A, Takizawa S.

PLoS One. 2014 Aug 22;9(8):e105319. doi: 10.1371/journal.pone.0105319. eCollection 2014.

45.

A Bead-based Normalization for Uniform Sequencing depth (BeNUS) protocol for multi-samples sequencing exemplified by HLA-B.

Hosomichi K, Mitsunaga S, Nagasaki H, Inoue I.

BMC Genomics. 2014 Aug 4;15:645. doi: 10.1186/1471-2164-15-645.

46.

Prognostic impact of M2 macrophages at neural invasion in patients with invasive ductal carcinoma of the pancreas.

Sugimoto M, Mitsunaga S, Yoshikawa K, Kato Y, Gotohda N, Takahashi S, Konishi M, Ikeda M, Kojima M, Ochiai A, Kaneko H.

Eur J Cancer. 2014 Jul;50(11):1900-8. doi: 10.1016/j.ejca.2014.04.010. Epub 2014 May 15.

PMID:
24835032
47.

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.

Ikeda M, Shiina S, Nakachi K, Mitsunaga S, Shimizu S, Kojima Y, Ueno H, Morizane C, Kondo S, Sakamoto Y, Asaoka Y, Tateishi R, Koike K, Arioka H, Okusaka T.

Invest New Drugs. 2014 Oct;32(5):928-36. doi: 10.1007/s10637-014-0109-2. Epub 2014 May 15.

48.

Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial.

Terazawa T, Kondo S, Hosoi H, Morizane C, Shimizu S, Mitsunaga S, Ikeda M, Ueno H, Okusaka T.

BMC Cancer. 2014 Apr 30;14:301. doi: 10.1186/1471-2407-14-301.

49.

[Liver cancer: progress in diagnosis and treatments. Topics: VI. Progress in treatments of liver cancer; 4. Molecularly targeted agent].

Ikeda M, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Okuyama H, Kuwahara A, Okusaka T.

Nihon Naika Gakkai Zasshi. 2014 Jan 10;103(1):93-101. Japanese. No abstract available.

PMID:
24605496
50.

Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.

Ikeda M, Ohkawa S, Okusaka T, Mitsunaga S, Kobayashi S, Morizane C, Suzuki I, Yamamoto S, Furuse J.

Cancer Sci. 2014 Apr;105(4):455-62. doi: 10.1111/cas.12368. Epub 2014 Mar 25.

Supplemental Content

Loading ...
Support Center